IGENOMIX

Paterna, Spain
Paterna, Spain
SEARCH FILTERS
Time filter
Source Type

News Article | May 8, 2017
Site: www.prnewswire.co.uk

Genetic disorders cannot be treated, but can only be avoided. Many parents are not aware that they are the carriers of inherited genetic disorders. And this lack of awareness has caused many children to be born with genetic disorders such as Thalassemia, Haemophilia, Cystic fibrosis and more in Arab population. Studies by World Health Organization (WHO) suggest that 10 in every 1000 live births suffer from genetic disorders. The numbers are alarming. "About 90% of the Arab population are carriers of at least one genetic disorder and about 19.7% of the couples in Arab nations are at a very high risk of having a child affected with genetic disorder," says Rupali Chopra from IGENOMIX. This is due to the fact that about 40-50% of marriages in Arab nations are consanguineous first cousin marriages. Amongst the most common genetic disorders, Alpha Thalassemia tops the list affecting 15.30% of the population. Thalassemia is a genetic blood disorder that affects a human body's ability to produce haemoglobin. This is a vital component of red blood cells that is responsible for carrying out oxygen to some of the most vital organs. The abnormal products of red blood cells is the reason why children remain blood deficient and have to rely on transfusion throughout their life. "We need to screen and find out who are carriers. Then, proper genetic counselling and steps need to be taken to ensure healthy children are born. Every life is important," says Gurpreet, a Thalassemia patient. Although there is no cure for genetic disorders, IGENOMIX's Carrier Genetic Test (CGT) can help parents prevent them. An important family planning test, CGT helps in determining who is a carrier in both the partners. If both the partners are carriers, there is 25% risk of having an affected child. If the high risk of transmitting a genetic disorder is identified or one or both partners are thalassemia patients themselves, the couples can opt for options like Preimplantation Genetic Diagnosis (PGD) to have a healthy baby. IGENOMIX  is a bio-technology company providing advanced services in reproductive genetics. Further information about the company at http://www.igenomix.com


Genetic disorders cannot be treated, but can only be avoided. Many parents are not aware that they are the carriers of inherited genetic disorders. And this lack of awareness has caused many children to be born with genetic disorders such as Thalassemia, Haemophilia, Cystic fibrosis and more in Arab population. Studies by World Health Organization (WHO) suggest that 10 in every 1000 live births suffer from genetic disorders. The numbers are alarming. "About 90% of the Arab population are carriers of at least one genetic disorder and about 19.7% of the couples in Arab nations are at a very high risk of having a child affected with genetic disorder," says Rupali Chopra from IGENOMIX. This is due to the fact that about 40-50% of marriages in Arab nations are consanguineous first cousin marriages. Amongst the most common genetic disorders, Alpha Thalassemia tops the list affecting 15.30% of the population. Thalassemia is a genetic blood disorder that affects a human body's ability to produce haemoglobin. This is a vital component of red blood cells that is responsible for carrying out oxygen to some of the most vital organs. The abnormal products of red blood cells is the reason why children remain blood deficient and have to rely on transfusion throughout their life. "We need to screen and find out who are carriers. Then, proper genetic counselling and steps need to be taken to ensure healthy children are born. Every life is important," says Gurpreet, a Thalassemia patient. Although there is no cure for genetic disorders, IGENOMIX's Carrier Genetic Test (CGT) can help parents prevent them. An important family planning test, CGT helps in determining who is a carrier in both the partners. If both the partners are carriers, there is 25% risk of having an affected child. If the high risk of transmitting a genetic disorder is identified or one or both partners are thalassemia patients themselves, the couples can opt for options like Preimplantation Genetic Diagnosis (PGD) to have a healthy baby. IGENOMIX  is a bio-technology company providing advanced services in reproductive genetics. Further information about the company at http://www.igenomix.com


This Global program recognizes outstanding industry achievements by companies worldwide. The methodology for determining Award recipients is unique - a deep dive research and analysis is conducted by Frost & Sullivan industry experts, which is presented to an esteemed and independent panel of Judges, comprising senior executives representing the top companies in the Middle East. The evening was gleaming with best of the people in buisness and technology from around the Arab region at Atlantis The Palm, Dubai on 24th May, 2017 where leaders became part of the proud moment shared by the team of 'Frost and Sullivan'. The success story of Igenomix Dubai Laboratory was sanctioned and sealed by the industry experts and our promise will continue to increase the quality of life by improving fertility rate among Middle Eastern population. Mr. Francisco Rodríguez, General Manager at Igenomix Middle East & India, after receiving the Frost & Sullivan Award, quoted: "We are humbled by this honour. Igenomix has dedicated years in research and development to attain the best genetic techniques that helps IVF specialists achieve higher pregnancy success rates globally, besides also preventing genetic disorders through our comprehensive state of the art screenings and diagnosis. This award recognises the technology and quality standards Igenomix commits to across the globe." "We were the first private genetic lab in 2016 to be accredited by CAP. Frost and Sullivan's award is yet another landmark for Igenomix. We have been able to successfully bring in the best genetic practices available globally to Middle East. Our customer support and quality reporting makes us unique and the most preferred genetics partner for many private and government medical bodies. We continuously keep upgrading our technologies to strive for accuracy and more comprehensive reporting," said Dr. Rupali Chopra, Lab Director, Igenomix Dubai. Igenomix offers specialized genetic services that include PGD (Preimplantation Genetic Diagnosis), PGS (Pre-Implantation Genetic Screening), CGT (Carrier Genetic Test), NACE (Non-invasive Prenatal Test) and ERA (Endometrial Receptivity Analysis). With more than 18 years of experience implementing new techniques and genetic services worldwide, Igenomix has an impressive Research & Development with significant visibility on future genetic applications.


This Global program recognizes outstanding industry achievements by companies worldwide. The methodology for determining Award recipients is unique - a deep dive research and analysis is conducted by Frost & Sullivan industry experts, which is presented to an esteemed and independent panel of Judges, comprising senior executives representing the top companies in the Middle East. The evening was gleaming with best of the people in buisness and technology from around the Arab region at Atlantis The Palm, Dubai on 24th May, 2017 where leaders became part of the proud moment shared by the team of 'Frost and Sullivan'. The success story of Igenomix Dubai Laboratory was sanctioned and sealed by the industry experts and our promise will continue to increase the quality of life by improving fertility rate among Middle Eastern population. Mr. Francisco Rodríguez, General Manager at Igenomix Middle East & India, after receiving the Frost & Sullivan Award, quoted: "We are humbled by this honour. Igenomix has dedicated years in research and development to attain the best genetic techniques that helps IVF specialists achieve higher pregnancy success rates globally, besides also preventing genetic disorders through our comprehensive state of the art screenings and diagnosis. This award recognises the technology and quality standards Igenomix commits to across the globe." "We were the first private genetic lab in 2016 to be accredited by CAP. Frost and Sullivan's award is yet another landmark for Igenomix. We have been able to successfully bring in the best genetic practices available globally to Middle East. Our customer support and quality reporting makes us unique and the most preferred genetics partner for many private and government medical bodies. We continuously keep upgrading our technologies to strive for accuracy and more comprehensive reporting," said Dr. Rupali Chopra, Lab Director, Igenomix Dubai. Igenomix offers specialized genetic services that include PGD (Preimplantation Genetic Diagnosis), PGS (Pre-Implantation Genetic Screening), CGT (Carrier Genetic Test), NACE (Non-invasive Prenatal Test) and ERA (Endometrial Receptivity Analysis). With more than 18 years of experience implementing new techniques and genetic services worldwide, Igenomix has an impressive Research & Development with significant visibility on future genetic applications.


Igenomix has recently been rewarded accreditation by College of American Pathologists (CAP) in Dubai (UAE), given its state-of-the-art facilities and cutting-edge products in the space of advanced reproductive genetics. The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government's own inspection program. The process is designed to ensure the highest standard of care for all laboratory patients. "The CAP Laboratory Accreditation Program's goal is to improve patient safety by advancing the quality of pathology and laboratory services through education, standard setting, and ensuring laboratories meet or exceed regulatory requirements. Igenomix is now the first Private Genetic Laboratory to be accredited by CAP in Middle East, which demonstrates the quality of the genetic testing services Igenomix delivers," said Dr. Rupali Chopra, Lab Director, Igenomix Dubai. Francisco Rodríguez, General Manager Igenomix, Middle East & India, upon learning of the laboratory's accreditation, said, "Igenomix becoming accredited by CAP is a great achievement and milestone, but most important is that doctors and patients can now be completely sure about Igenomix commitment and conviction of providing the best quality genetic services." Igenomix is one of the world's leading providers of advanced services in reproductive genetics. Currently operating from eight laboratories worldwide, has aggressive expansion plans to set foot in many new geographies including Canada and Turkey which will be operational soon. The global team of experts led by Prof. Dr. Carlos Simon, Professor of Obstetrics and Gynaecology at Valencia University and Stanford School of Medicine, Chief Scientific Officer and also a key shareholder of Igenomix, has come up with some path-breaking genetics services to support the specialists in the field of reproductive medicine over last few years. Specialist services offered by IGENOMIX include PGS (PreImplantation Genetic Screening) with the added advantage of MitoScore, NACE (Non invasive Analysis of Chromosomal Examination); CGT (Carrier Genetic Test); PGD (Preimplantation Genetic Diagnosis) and ERA (Endometrial Receptivity Analysis). Igenomix is a biotechnology company that provides advanced services in reproductive genetics. Our broad experience and advanced research ability make us one of the global leaders in this field, and we make sure we offer effective solutions adapted to different infertility problems. For further information about the company visit: http://www.igenomix.com


Diaz-Gimeno P.,University of Valencia | Horcajadas J.A.,IGenomix | Martinez-Conejero J.A.,IGenomix | Esteban F.J.,University of Jaén | And 4 more authors.
Fertility and Sterility | Year: 2011

Objective: To create a genomic tool composed of a customized microarray and a bioinformatic predictor for endometrial dating and to detect pathologies of endometrial origin. To define the transcriptomic signature of human endometrial receptivity. Design: Two cohorts of endometrial samples along the menstrual cycle were used: one to select the genes to be included in the customized microarray (endometrial receptivity array [ERA]), and the other to be analyzed by ERA to train the predictor for endometrial dating and to define the transcriptomic signature. A third cohort including pathological endometrial samples was used to train the predictor for pathological classification. Setting: Healthy oocyte donors and patients. Patient(s): Healthy fertile women (88) and women with implantation failure (5) or hydrosalpinx (2). Intervention(s): Human endometrial biopsies. Main Outcome Measure(s): The gene expression of endometrial biopsies. Result(s): The ERA included 238 selected genes. The transcriptomic signature was defined by 134 genes. The predictor showed a specificity of 0.8857 and sensitivity of 0.99758 for endometrial dating, and a specificity of 0.1571 and a sensitivity of 0.995 for the pathological classification. Conclusion(s): This diagnostic tool can be used clinically in reproductive medicine and gynecology. The transcriptomic signature is a potential endometrial receptivity biomarkers cluster. © 2011 American Society for Reproductive Medicine, Published by Elsevier Inc.


Labarta E.,University of Valencia | MartInez-Conejero J.A.,IGenomix | Alama P.,University of Valencia | Horcajadas J.A.,IGenomix | And 3 more authors.
Human Reproduction | Year: 2011

Background: Elevated serum progesterone levels at the end of the follicular phase in controlled ovarian stimulation (COS) leads to a poorer ongoing pregnancy rate in IVF cycles due to reduced endometrial receptivity. The objective of this study was to use microarray technology to compare endometrial gene expression profiles at the window of implantation according to the levels of circulating progesterone. Methods: For this prospective cohort study, microarray data were obtained from endometrial biopsies from 12 young healthy oocyte donors undergoing COS with pituitary suppression by either gonadotrophin-releasing hormone (GnRH) agonists or antagonists, and recombinant FSH. On the day of recombinant chorionic gonadotrophin (rCG) administration, six women had serum progesterone levels (P) >1.5 ng/ml (study group) and six had serum P levels <1.5 ng/ml (control group). Endometrial samples were collected using a Pipelle catheter 7 days after the rCG injection. Results: Using the parametric test, we identified 140 genes significantly dysregulated (64 up- and 76 down-regulated) in the study group endometria compared with the control endometria, regardless of the GnRH analogue employed. These genes are related to cell adhesion, developmental processes, the immune system and others, which are all required for normal endometrial function development. Of the 25 gene targets previously proposed as markers for endometrial receptivity, 13 appeared over-regulated in the study group. Conclusions: Our Results: reveal that elevated progesterone levels on the day of rCG administration can induce significant alterations in the gene expression profile of the endometrium. © 2011 The Author.


DUBAI, UAE, November 14, 2016 /PRNewswire/ -- Igenomix has recently been rewarded accreditation by College of American Pathologists (CAP) in Dubai (UAE), given its state-of-the-art facilities and cutting-edge products in the space of advanced reproductive genetics. The U.S....


News Article | March 2, 2017
Site: www.prnewswire.co.uk

Conceiving and bearing a child is a blessing in a couple's life. While they are lost in rejoicing the good news, they often ignore the fact that they can be passing some serious genetic disorders to their child. Along with the features and traits, a child also inherits genetic disorders which their parents are the carrier. According to World Health Organization (WHO), 10 in every 1000 live births suffer from genetic disorders. Genetic disorders are a type of disorders that run in the family genes. "You might not be aware of it, but you could be a carrier of a disorder. In Arab countries where 40% to 50% of Consanguinity first cousins marriages takes place, the risk of having a child affected with a genetic disorder is as high as 19.7%," says Dr. Rupali Chopra from IGENOMIX. Genetic disorders are one of the leading causes of infant mortality in the Arab countries. Alpha Thalassemia, Glycine Encephalopathy, Haemochromatosis, Cystic Fibrosis, Polycystic Kidney Disorders are the most common genetic disorders prevailing in the Arab countries. Alpha Thalassemia is the most predominant genetic disorder affecting 15.30% of the population. Genetic disorders are not curable, but they can be prevented with IGENOMIX's Carrier Genetic Test (CGT). CGT is an important family planning test to determine the risk of having a child affected with genetic disorders. CGT is carried out with a simple blood test that can prevent serious genetic disorders. Many of these disorders are without treatment and many of them are fatal. Dr. Rupali adds "If both the partners are carriers of the genetic disorder, there is an increase in the risk of having an affected child, approximately by 25%. If high risk of transmitting a genetic disorder is identified, the couples should go for Preimplantation Genetic Diagnosis (PGD)." PGD screens the embryos for the genetic mutation wherein both the parents are a carrier of genetic disorder. PGD enables selection of those embryos which are not affected by the genetic disorder. Couples who are already undergoing IVF should consider additional pre-conception screening to identify any genetic disorder which their baby might be at an increased risk of developing. IGENOMIX is a bio-technology company providing advanced services in reproductive genetics. Further information about the company at http://www.igenomix.com


News Article | March 2, 2017
Site: www.prnewswire.com

DUBAI, UAE, March 2, 2017 /PRNewswire/ -- Conceiving and bearing a child is a blessing in a couple's life. While they are lost in rejoicing the good news, they often ignore the fact that they can be passing some serious genetic disorders to their child. Along with the features and...

Loading IGENOMIX collaborators
Loading IGENOMIX collaborators